STOCK TITAN
  1. Home
  2. News
  3. BETRF

BetterLife Pharma Inc - BETRF STOCK NEWS

Welcome to our dedicated news page for BetterLife Pharma (Ticker: BETRF), a resource for investors and traders seeking the latest updates and insights on BetterLife Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BetterLife Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BetterLife Pharma's position in the market.

News
BetterLife Pharma Inc. to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Rhea-AI Summary
BetterLife Pharma Inc. (BETRF) will present at the 2024 Bloom Burton & Co. Healthcare Investor Conference, showcasing their focus on mental disorder treatments. The event will feature key executives discussing the company's initiatives and engaging with potential investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.79%
Tags
conferences
-
News
BetterLife To Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Rhea-AI Summary
BetterLife Pharma Inc. announces participation in Bloom Burton Healthcare Investor Conference and resolution of a claim by issuing common shares valued at $19,687.50.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.71%
Tags
conferences
-
News
BetterLife Announces Closing of $1.168 Million Convertible Debentures to Further Advance IND-enabling Studies of its Non-hallucinogenic LSD-based Drug Candidate BETR-001
Rhea-AI Summary
BetterLife Pharma Inc. closes $1.168 million convertible debentures to advance BETR-001 development, a non-hallucinogenic derivative of LSD, targeting anxiety and depression disorders. FDA's breakthrough therapy designation for LSD in anxiety disorders validates BetterLife's research efforts. BETR-001 shows promising preclinical data with improved safety profile over LSD. Dr. Doroudian and Dr. Sangha, insiders of the company, subscribed for $100,000 each in the private placement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
none
News
BetterLife’s 2-Bromo-LSD for Treatment of Depression Highlighted by Carleton University
Rhea-AI Summary
BetterLife Pharma Inc. announces the development of 2-bromo-LSD for treating depression, with BETR-001 entering human trials in 2024. The company closes $65,000 in convertible debentures and plans further private placements for advancing BETR-001 and general working capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.75%
Tags
none
-
News
BetterLife Announces Closing of Convertible Debentures For Further Development of BETR-001
Rhea-AI Summary
BetterLife Pharma Inc. (BETR) closes $300,000 convertible debentures to advance development of BETR-001, a non-hallucinogenic derivative of LSD, for mental disorders treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.83%
Tags
none
-
News
BetterLife Announces Closing of a Private Placement
Rhea-AI Summary
BetterLife Pharma Inc. (BETR) has closed a non-brokered private placement, issuing 2,000,000 units at $0.10 per unit, generating $200,000 in gross proceeds. Each unit includes one common share and one warrant, with Dr. Ahmad Doroudian, the CEO, subscribing for 1,000,000 units. The private placement is exempt from certain regulatory requirements due to the company not being listed on a specified stock exchange.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.87%
Tags
none
News
BetterLife Announces Extension of Warrants
Rhea-AI Summary
BetterLife Pharma Inc. (BETR) extends the expiry date of 6,386,298 outstanding share purchase warrants to December 2, 2025, with an original exercise price of $0.60. The warrants were granted pursuant to the exercise of the Company’s December 2020 private placement offering of special warrants. Previously issued warrant certificates remain valid and enforceable until the amended expiry date. Warrantholders may exercise their warrants by following the specified procedure.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15%
Tags
none
-
News
US Patent and Trademark Office Publishes BetterLife’s Comprehensive Patent for BETR-001 and Other LSD Derivatives
Rhea-AI Summary
BetterLife Pharma Inc. (BETR) announces the publication of its patent application for BETR-001 and LSD derivatives by the US Patent and Trademark Office. The application covers the development of non-hallucinogenic derivatives of LSD for the treatment of neuropsychiatric and neurological conditions, including depression, anxiety, cluster headaches, and neuropathic pain. The company's efforts in developing novel therapies for mental disorders were also recognized in The Atlantic, highlighting the potential of the BETR-001 program. BETR-001 is projected to enter human trials in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
none
-
News
BetterLife Pharma to Host Investors Update Call on September 18, 2023
Rhea-AI Summary
BetterLife Pharma Inc. to host investor update Zoom call on September 18, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
News
BetterLife Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001
Rhea-AI Summary
BetterLife Pharma Inc. completes 4-week toxicology study for BETR-001, showing well-tolerated repeat dosing and broad therapeutic window in humans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
none
Stock BETRF logo
BetterLife Pharma Inc

OTC:BETRF

BETRF Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

BETRF Stock Data

8.42M
86.77M
22.64%
0%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Canada
Vancouver

About BETRF

learn about working at palisade investments. join linkedin today for free. see who you know at palisade investments, leverage your professional network, and get hired.